[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"focused-ultrasound\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:focused-ultrasound":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,68,93],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100592197","focused-ultrasound-spleen-stimulation-and-inflammation-in-septic-shock-100592197",false,"NCT06990295","Focused Ultrasound Spleen Stimulation and Inflammation in Septic Shock","Effects of Focused Ultrasound Spleen Neuromodulation on Inflammatory Cytokine Levels in Patients With Septic Shock: A Randomized Controlled Pilot Trial","Inclusion Criteria:\n\n* Age ≥ 18 years, regardless of sex\n* Diagnosed with septic shock according to Sepsis-3 criteria: Sequential Organ Failure Assessment (SOFA) score ≥ 2 and requiring vasopressor support to maintain a mean arterial pressure (MAP) ≥ 65 mmHg.\n* Admitted to the ICU within 24 hours of septic shock diagnosis\n* Expected to require intensive care for at least 72 hours\n* Informed consent obtained from the patient or legal representative\n\nExclusion Criteria:\n\n* Known pregnancy or breastfeeding\n* Participation in another interventional clinical trial within 30 days\n* Known immunodeficiency or ongoing immunosuppressive therapy\n* Malignancy with life expectancy \\\u003C 6 months\n* Contraindications to focused ultrasound (e.g., splenic trauma, splenectomy, local skin infection)\n* Do-not-resuscitate (DNR) order or expected death within 24 hours\n* Any other condition deemed unsuitable for participation by the investigators","ALL","18 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study evaluates the safety and effectiveness of focused ultrasound spleen neuromodulation in patients with septic shock, a life-threatening condition characterized by excessive inflammation and organ dysfunction. The primary objective is to determine whether non-invasive, focused ultrasound stimulation of the spleen can reduce circulating inflammatory cytokine levels in this patient population.\n\nEligibility Criteria:\n\nAdults aged 18 years or older Diagnosed with septic shock and admitted to the ICU within 24 hours Expected to require intensive care for at least 72 hours\n\nStudy Protocol:\n\nParticipants will be randomly assigned to one of two groups:\n\nIntervention Group: Will receive standard septic shock care plus twice-daily focused ultrasound stimulation over the spleen for five days, using a portable device.\n\nControl Group: Will receive standard septic shock care alone. Blood samples will be collected at baseline and Day 5 to measure inflammatory cytokine levels, including TNF-α, IL-1β, IL-6, and IL-10. Additional assessments will include lymphocyte subpopulations, organ function scores, ICU length of stay, 28-day mortality, and adverse events.\n\nOutcome Measures:\n\nPrimary: Change in levels of inflammatory cytokines on Day 5. Secondary: Changes in organ function (SOFA score), ICU length of stay, 28-day survival, and safety\u002Ftolerability of the intervention.",[26,27,28,29,30],"Septic Shock","Inflammatory Cytokines","Spleen Neuromodulation","Focused Ultrasound","Critical Care",[26,29,28,27,30,32,33],"Immune Modulation","Pilot Study","RECRUITING","2026-05-15",{"date":37,"type":38},"2026-05-19","ACTUAL",{"date":40,"type":38},"2025-07-25",{"date":42,"type":20},"2026-12-31",{"name":44,"class":45},"First Affiliated Hospital of Wannan Medical College","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":46},"100546142","neuromodulation-effect-of-focused-ultrasound-for-motor-recovery-in-patients-with-stroke-100546142","NCT06391086","Neuromodulation Effect of Focused Ultrasound for Motor Recovery in Patients With Stroke","Inclusion Criteria:\n\n* Patients with stroke (including hemorrhagic or ischemic stroke) diagnosed by a board-certificated physician.\n* Occurrence of stroke within three months.\n* Upper limb muscle strength ≤ 4 points according to the Medical Research Council Manual Muscle Testing scale.\n* No previous history of stroke, epilepsy, dementia, Parkinson's disease, or other neurodegenerative diseases.\n* Patients could maintain sitting posture for more than 15 minutes on a chair.\n* 18 years of age or older.\n\nExclusion Criteria:\n\n* History of recurrent stroke, traumatic brain injuries, brain tumors, spinal cord injury, Parkinson's disease or other musculoskeletal system diseases that may affect evaluation and treatment.\n* Contraindications to focused ultrasound, including pregnancy, cardiac pacemaker or implantable medical device, abnormal connective tissue diseases, coagulopathy (PLT\\\u003C100,000\u002FμL, PT\\>14 seconds, APTT\\>36 seconds, INR\\>1.3), implants near or in the brain, or those deemed Unsuitable for this treatment by the physician.\n* Unable to cooperate with treatment or functional assessment due to impaired consciousness or aphasia; inability to informed consent.\n* Patient with cranial bone factor causing the inability of tFUS penetration.\n* Patient under anticoagulants with coagulopathy (PLT\\\u003C100,000\u002FμL, PT\\>14 seconds, APTT\\>36 seconds, INR\\>1.3)\n* Patients who are not suitable for undergoing CT imaging examination;\n* Major physical illnesses and neurological disorders (such as epilepsy, brain surgery, etc.)\n* Patients with metallic implants in their bodies;\n* Patients taking tricyclic antidepressants, analgesics, or using antiepileptic drugs\n* Individuals experiencing sleep disorders during tFUS treatment;\n* Individuals with history of alcoholism\n* Patients with severe or uncontrollable intracranial pressure;\n* Patients requiring anticoagulants;\n* Any intracranial space-occupying lesions;\n* Significant calcification of intracranial vessels based on pre-treatment CT imaging;\n* Subjects with lesions\u002Fwounds on the scalp in the target region.",{"count":54,"type":20},50,[23],"Transcranial focused ultrasound (tFUS) can be used as a non-invasive brain neuromodulation technique. Low-intensity focused ultrasound has been demonstrated to be safe and have neuromodulatory effects on the cerebral cortex in healthy human and animal experiments.This study aims to investigate the effect of tFUS on cortical excitability for motor recovery in patients with stroke.",[29,58],"Stroke","2026-04-08",{"date":61,"type":38},"2026-04-13",{"date":63,"type":38},"2024-08-01",{"date":65,"type":20},"2029-10-01",{"name":67,"class":45},"National Taiwan University Hospital",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":21,"phases":76,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":46},"100538565","focused-ultrasound-for-drug-resistant-epilepsy-100538565","NCT06292494","Focused Ultrasound for Drug-resistant Epilepsy","Inclusion Criteria:\n\n* Patients aged 20 and above.\n* Localized refractory epilepsy (ineffective with maximum doses of two or more anti-seizure medications).\n* Seizure frequency records for at least one month prior to the trial.\n* Patients who have undergone a complete preoperative examination, including EEG, MRI, and positron emission tomography (PET).\n* Capable of undergoing high-resolution computed tomography (CT scan), and SDR (Skull Density Ratio) ≥ 0.3.\n* Must have a body type suitable for entry into the magnetic resonance imaging (MRI) machine and be able to tolerate MRI scans.\n* During the surgical procedure, communication with the physician and the expression of sensory perceptions are essential; general anesthesia is not required.\n* Must be able to voluntarily press the stop button.\n* Willing to undergo removal of hair from the treatment site.\n\nExclusion Criteria:\n\n* This product is not suitable for individuals with contraindications related to MRI, such as those with metallic implants, those unable to undergo MRI, severe claustrophobia, or those with adverse reactions to contrast agents.\n* Individuals with implants in the brain or skull, such as shunts, electrodes, hard brain membrane patches, or electrode plates, that cannot be avoided along the expected path of brain ultrasound.\n* Patients along the expected path of brain ultrasound who cannot avoid structures or sensitive tissues with energy absorption (e.g., previous brain shunt surgery sites, surgical metal clips, or any hard implants).\n* Patients with extensive scabbing along the expected path of brain ultrasound.\n* Patients who have used contrast agents (e.g., MRI, ultrasound) within the past 24 hours before treatment.\n* Patients with other high-risk brain disorders (e.g., intracranial aneurysm).\n* Patients with intraoperative or postoperative bleeding risk:\n\n  1. Those with a history of cerebrovascular disease (multiple strokes or strokes within the past six months) or a history of cerebral hemorrhage and stroke.\n  2. Those with abnormal bleeding, intracranial bleeding, coagulation disorders, or a history of bleeding or clotting disorders, either during or after surgery.\n* Patients taking or injecting anticoagulant medications such as aspirin, coumadin, heparin, novel oral anticoagulants (NOACs), etc., which may lead to prolonged bleeding. Medication should be discontinued for 3-7 days before treatment.\n* Patients with severe uncontrolled hypertension (systolic blood pressure \\> 180 mmHg after stable medication, diastolic blood pressure \\> 100 mmHg).\n* Patients unable to communicate with the physician during the treatment process.\n* Unstable cardiac conditions (heart rate \\> 180 beats\u002Fminute or \\\u003C 40 beats\u002Fminute; systolic blood pressure \\> 180 mmHg or \\\u003C 90 mmHg).\n* Substance abuse (use of illegal drugs or using medications in a manner not recommended by a physician or manufacturer) or alcohol addiction.\n* Patients who have taken medications affecting the central nervous system within the past six months (e.g., central nervous system stimulants, sympathomimetic agents).\n* Patients with psychological abnormalities (e.g., schizophrenia, severe depression, bipolar disorder).\n* Individuals with severe head surface injuries or potential allergies to materials in contact with the head (such as conductive gels, head silicone membranes)",{"count":75,"type":20},20,[23],"Focused ultrasound (FUS) has been shown to differentially lesion or modulate (excite and inhibit) brain circuit and neural activity across a broad range of acoustic stimulus parameters (intensity, duty cycle, pulse repetition frequency and pulse duration) for decades. From our previous study, FUS sonication may suppress the number of epileptic signal bursts observed in EEG recordings after the induction of acute epilepsy. The presence of the suppressive effect was found in terms of the number of epileptic EEG spikes from the analysis of the unfiltered and theta-band EEG activity, and further discontinue the seizure attacks. EEG activity has also been consistently reported to have a positive correlation with the level of epilepsy, and FUS-mediated reduction of epileptic EEG activity was most notably observed, no matter lesioning or modulating effects. The aims of this study are to demonstrate the safety and efficacy of FUS technology in epilepsy patients and to estimate the optimal parameters of focused ultrasound exposure that will be used in the case of epilepsy.",[29,79,80,81,82],"MR-guided FUS","Drug Refractory Epilepsy","Drug Resistant Epilepsy","Medication Resistant Epilepsy","2025-09-02",{"date":85,"type":38},"2025-09-09",{"date":87,"type":38},"2024-01-01",{"date":89,"type":20},"2027-12-31",{"name":91,"class":92},"Taipei Veterans General Hospital, Taiwan","OTHER_GOV",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":99,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":102,"phases":4,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":4},"100440048","focused-ultrasound-for-the-treatment-of-pancreatic-cancer---an-international-registry-100440048","NCT05010226","Focused Ultrasound for the Treatment of Pancreatic Cancer - an International Registry","Inclusion Criteria:\n\n* In order to be eligible to participate in this registry, an individual must meet all of the following criteria:\n\n  1. 20 years and older\n  2. Provision of signed and dated informed consent form\n  3. Stated willingness to comply with all registry procedures and availability for the duration of the registry\n  4. Histology proven pancreatic carcinoma in any area of pancreas\n  5. Pancreatic tumor that can be treated by FUS\n  6. Willingness and ability to complete follow-up interviews\n  7. Patients have agreed to participate in the clinical trial 201701032DIPD and were scheduled to receive FUS therapy in our hospital\n\nExclusion Criteria:\n\n* An individual who meets any of the following criteria will be excluded from participation in this registry:\n\n  1. Any disease, condition or surgery which would result in a contraindication to undergoing FUS therapy.\n  2. Clinical trials of pancreatic cancer not of focused ultrasound or related activities","20 Years",{"count":101,"type":20},30,"OBSERVATIONAL","The purpose of the registry is to collect data on the performance of the focused ultrasound (FUS) technology and health outcomes. A wide variety of approaches exist for using FUS on pancreatic cancer patients, and the primary goal is to capture this broad spectrum of approaches and their impact on patients overall health. This information will help provide a better understanding of current care, and may possibly direct further, more specific investigations that will follow this registry.",[105,29],"Pancreatic Cancer","NOT_YET_RECRUITING","2021-08-10",{"date":109,"type":38},"2021-08-18",{"date":111,"type":20},"2021-09",{"date":113,"type":20},"2026-09",{"name":67,"class":45}]